• Policy
• It will not be easy to reflect generic positive list system
• by Lee, Tak-Sun Apr 6, 2022 06:05am

• Company
• Sales of AZ COVID vaccine increased 32% to 655.3 billion won
• by Apr 6, 2022 06:05am

• Company
• Sales of MSD in Korea exceeded 500 billion won
• by Apr 5, 2022 09:32am

• Company
• Imbruvica fails CDDC twice and reattempts 1st-line reimb.
• by Eo, Yun-Ho Apr 5, 2022 05:59am

• Opinion
• [Reporter's view] Commercialization of innovative new drugs
• by Lee, Tak-Sun Apr 5, 2022 05:58am

• Product
• Lagevrio prescriptions exceed 2,000… Paxlovid's up 25.6%
• by Kang, Shin-Kook Apr 5, 2022 05:58am

• Policy
• Kymriah has been listed, hope of cure
• by Lee, Jeong-Hwan Apr 5, 2022 05:57am

• Company
• AZ starts next-gen ADC dev with confidence from Enhertu
• by Apr 4, 2022 06:07am

• Policy
• Phase 3 of Jetema the toxin will be conducted in Korea
• by Lee, Hye-Kyung Apr 4, 2022 06:07am

• Policy
• 20 ultra-high-priced drugs over ₩5 mil sold in Korea
• by Lee, Tak-Sun Apr 4, 2022 06:07am